NCT02593331View on ClinicalTrials.gov

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of BFKB8488A in Otherwise Healthy Overweight and Obese Participants With Likely Insulin Resistance

PHASE1CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

October 29, 2015

Primary Completion Date

March 28, 2017

Study Completion Date

March 28, 2017

Conditions
Insulin Resistance
Interventions
DRUG

BFKB8488A

Participants will receive either a single escalated dose of BFKB8488A administered SC or a single dose of BFKB8488A administered IV on Day 1.

OTHER

Placebo

Participants will receive a single dose of placebo on Day 1.

Trial Locations (1)

91911

Profil Institute for Clinical Research Inc., Chula Vista

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY